Atorvastatin calcium
Synonyms:1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-, (betaR,deltaR)-rel-; Atorvastatin calcium [USAN]; Lipitor (TN);
Atorvastatin Calcium (amorphous); calcium (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-yl-pyrrol-1-yl]-3,5-dihydroxy-heptanoate;
(3S,5S)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-yl-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid; CI-981;
(1betaR,deltaR)-2-(p-Fluorophenyl)-beta,delta-dihydroxy-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrole-1-heptanoic acid; Atorvastatin (R*,R*); Calcium
(betaR,deltaR)-2-(p-fluorophenyl)-beta,delta-dihydroxy-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrole-1-heptanoate (1:2); Atrovastatin; (3R,5R)-7-[2-(4-Fluorophenyl)-5-Isopropyl-3-Phenyl-;
CAS Registry Number:134523-03-8
Molecular Formula:C66H68CaF2N4O10
Molecular Weight:558.639803
Appearance:White Crystalline Powder
Boiling Point:722.2 °C at 760 mmHg
Melting Point:176-178°C
Flash Point:390.6 °C
Biological Activity:Potent HMG-CoA reductase inhibitor (IC 50 = 8 nM). Reduces circulating LDL-C by inhibiting cholesterol biosynthesis and inducing expression of LDL receptors. Inhibits smooth
muscle cell proliferation in vitro and exhibits antinociceptive effects in the inflammatory hypernociception model.
Usage:A selective, competitive HMG-CoA reductase inhibitor. The only drug in its class specfically indicated for lowering both elevated LDL-cholesterol and triglycerides in patients with
hypercholesterolemia